Testing new drugs to lower Lp(a) cholesterol
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests two new drugs, alone and together, to lower a type of cholesterol called Lp(a) that increases heart disease risk. You may qualify if you have high Lp(a) and your LDL cholesterol is still high despite current treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your Lp(a) level must be at least 20 mg/dL (and may need to be higher depending on the group).
- Your bad cholesterol (LDL) must be above 70 mg/dL.
- Your triglycerides (another blood fat) must be under 400 mg/dL.
- Your blood sugar control must be good (HbA1c under 10%, fasting sugar under 270 mg/dL).
- You must not have had a heart attack, stroke, or related event in the past 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial helps people with high cholesterol or a history of heart disease find the best treatment to lower their risk of future heart problems. It tests a program to optimize lipid-lowering therapy.
This study compares two new medicines—obicetrapib and bempedoic acid—to see which one better lowers cholesterol in people whose cholesterol remains high despite taking standard medications. If your cholesterol isn't controlled well enough with current drugs, this trial may help you access an experimental treatment.
This trial tests a combination medication (obicetrapib plus ezetimibe) taken daily to lower cholesterol and triglycerides in people with type 2 diabetes or metabolic syndrome who are already on standard cholesterol treatment. It may help reduce heart risks.
This study tests an oral medicine (HRS-5346) to lower lipoprotein(a), a type of fat in the blood linked to heart problems. It might help people with high levels who are at increased risk for heart attacks or strokes.
This study tests whether a new medicine called lepodisiran can shrink plaque in heart arteries for adults with high Lp(a) (a type of cholesterol linked to heart disease) who have had a heart event or are at serious risk. The trial uses CT scans to monitor changes in your arteries.
This study looks at levels of a type of cholesterol called Lp(a) in people with certain heart and blood vessel diseases. The goal is to understand how common high Lp(a) is in Russian adults with these conditions.
Hear when a new Dyslipidemias trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.